Anti-angiogenic and anti-tumor activities of 2′-hydroxy-4′-methoxychalcone

被引:88
作者
Lee, Yeon Sil
Lim, Soon Sung
Shin, Kuk Hyun
Kim, Yeong Shik
Ohuchi, Kazuo
Jung, Sang Hoon
机构
[1] Korea Inst Sci & Technol, Nat Prod Res Ctr, Seoul 136791, South Korea
[2] Hallym Univ, Silver Biotechnol Res Ctr, Chunchon 220702, South Korea
[3] Seoul Natl Univ, Coll Pharm, Nat Prod Res Inst, Seoul 110460, South Korea
[4] Tohoku Univ, Grad Sch Pharmaceut Sci, Lab Pathophysiol Biochem, Sendai, Miyagi 9808578, Japan
关键词
2 '-hydroxy-4 '-methoxychalcone; angiogenesis; calf pulmonary arterial endothelial cell; proliferation;
D O I
10.1248/bpb.29.1028
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
In the present study, we evaluated the in vitro and in vivo anti-angiogenic and anti-tumor activities of 2'-hydroxy-4'-methoxychalcone (HMC). HMC decreased angiogenesis in both chick embryos in the chorioallantoic membrane assay and basic fibroblast growth factor (bFGF)-induced vessel formation in the mouse Matrigel plug assay. This compound also reduced the proliferation of calf pulmonary arterial endothelial cells and was found to possess relatively weak gelatinase/collagenase inhibitory activity in vitro. HMC, when administered subcutaneously at the dose of 30 mg/kg for 20 d to mice implanted with murine Lewis lung carcinoma, caused a significant inhibition of tumor volume by 27.2%. Intraperitoneal (i.p.) treatment at the same dosage for 10 d to ICR mice bearing sarcoma 180 caused a significant suppression in tumor weight by 33.7%. Taken together, out data demonstrate that the anti-angiogenic activities of HMC might be due to anti-proliferative activity under inhibition of the induction of COX-2 enzyme. Furthermore, the results suggest that the potent anti-angiogenic activity of HMC seems to be the possible mechanism of action in these animal models of solid tumors.
引用
收藏
页码:1028 / 1031
页数:4
相关论文
共 21 条
[1]   Anti-tumor activities of chondroitinase AC and chondroitinase B: inhibition of angiogenesis, proliferation and invasion [J].
Denholm, EM ;
Lin, YQ ;
Silver, PJ .
EUROPEAN JOURNAL OF PHARMACOLOGY, 2001, 416 (03) :213-221
[2]   Clinical applications of angiogenic growth factors and their inhibitors [J].
Ferrara, N ;
Alitalo, K .
NATURE MEDICINE, 1999, 5 (12) :1359-1364
[3]   ANGIOGENESIS IN CANCER, VASCULAR, RHEUMATOID AND OTHER DISEASE [J].
FOLKMAN, J .
NATURE MEDICINE, 1995, 1 (01) :27-31
[4]   Chalcones: An update on cytotoxic and chemoprotective properties [J].
Go, ML ;
Wu, X ;
Liu, XL .
CURRENT MEDICINAL CHEMISTRY, 2005, 12 (04) :483-499
[5]   A flanking attack on cancer [J].
Hanahan, D .
NATURE MEDICINE, 1998, 4 (01) :13-14
[6]   Selective inhibition of vascular endothelial growth factor-mediated angiogenesis by cyclosporin A:: Roles of the nuclear factor of activated T cells and cyclooxygenase 2 [J].
Hernández, GL ;
Volpert, OV ;
Iñiguez, MA ;
Lorenzo, E ;
Martínez-Martínez, S ;
Grau, R ;
Fresno, M ;
Redondo, JM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2001, 193 (05) :607-620
[7]   Regulation of angiogenic growth factors in the female reproductive tract by estrogens and progestins [J].
Hyder, SM ;
Stancel, GM .
MOLECULAR ENDOCRINOLOGY, 1999, 13 (06) :806-811
[8]  
Kim YP, 2001, J PHARM PHARMACOL, V53, P1295, DOI 10.1211/0022357011776586
[9]  
Koch AE, 1998, ARTHRITIS RHEUM-US, V41, P951, DOI 10.1002/1529-0131(199806)41:6<951::AID-ART2>3.0.CO
[10]  
2-D